Immunic Inc - Understand $imux stock

$IMUX Market Cap: $161.2 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$95.31M

TTM

Current Assets

$84.98M

Q2 2024

Current Liabilities

$22.68M

Q2 2024

Current Ratio

374.73%

Q2 2024

Total Assets

$86.49M

Q2 2024

Total Liabilities

$22.92M

Q2 2024

Book Value

$63.57M

Q2 2024

Cash

$79.70M

Q2 2024

P/E

-1.692

Sep 18, 2024 EST

Free Cash Flow

-$72.75M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue										$0.00	$0.00	$0.00	$0.00
Gross Profit										$0.00	$0.00	$0.00	$0.00
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$16.01M	$15.26M	$13.30M	$10.33M	$14.52M	$13.59M	$13.31M	$11.22M	$12.35M	$10.86M	$9.620M	$4.480M	$3.070M
YoY Change	4.88%	14.76%	28.75%	-28.86%	6.84%	2.1%	18.63%	-9.15%	13.72%	12.89%	114.73%	45.93%
% of Gross Profit
Research & Development	$83.22M	$71.26M	$61.12M	$38.64M	$22.51M	$9.595M	$39.34M	$30.05M	$39.77M	$39.48M	$21.79M	$5.097M	$5.520M
YoY Change	16.78%	16.59%	58.18%	71.63%	134.62%	-75.61%	30.94%	-24.46%	0.74%	81.2%	327.45%	-7.66%
% of Gross Profit
Depreciation & Amortization	$111.0K	$77.00K	$85.00K	$39.00K	$50.00K	$15.00K	$998.0K	$1.808M	$1.328M	$1.087M	$799.0K	$651.0K	$960.0K
YoY Change	44.16%	-9.41%	117.95%	-22.0%	233.33%	-98.5%	-44.8%	36.14%	22.17%	36.05%	22.73%	-32.19%
% of Gross Profit
Operating Expenses	$99.22M	$119.5M	$91.67M	$48.97M	$37.03M	$12.00M	$52.66M	$41.27M	$52.12M	$50.34M	$31.40M	$9.580M	$8.580M
YoY Change	-16.96%	30.35%	87.18%	32.24%	208.68%	-77.22%	27.6%	-20.83%	3.53%	60.31%	227.79%	11.66%
Operating Profit	-$99.22M	-$119.5M	-$91.67M	-$48.97M	-$37.03M	-$12.00M	-$52.66M	-$41.27M	-$52.12M	-$50.34M	-$31.40M	-$9.580M	-$8.580M
YoY Change	-16.96%	30.35%	87.18%	32.24%	208.68%	-77.22%	27.6%	-20.83%	3.53%	60.31%	227.79%	11.66%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$3.075M	$1.041M	$66.00K	$60.00K	$110.0K	$520.0K	$650.0K	$280.0K	$60.00K	$20.00K	$10.00K	$413.0K	-$9.250M
YoY Change	195.39%	1477.27%	10.0%	-45.45%	-78.85%	-20.0%	132.14%	366.67%	200.0%	100.0%	-97.58%	-104.46%
% of Operating Profit
Other Income/Expense, Net	$5.611M	-$919.0K	-$1.280M	$4.954M	$2.099M	$455.0K	$577.0K	$297.0K	$97.00K	$2.675M	-$1.316M	$2.879M	$11.95M
YoY Change	-710.55%	-28.2%	-125.84%	136.02%	361.32%	-21.14%	94.28%	206.19%	-96.37%	-303.27%	-145.71%	-75.91%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$93.61M	-$120.4M	-$92.95M	-$44.02M	-$34.93M	-$41.48M	-$52.08M	-$40.97M	-$52.02M	-$47.67M	-$32.72M	-$6.701M	-$5.880M
YoY Change	-22.25%	29.55%	111.14%	26.02%	-15.78%	-20.36%	27.12%	-21.25%	9.14%	45.69%	388.26%	13.96%
Income Tax													$0.00
% Of Pretax Income
Net Earnings	-$93.61M	-$120.4M	-$92.95M	-$44.02M	-$34.93M	-$11.54M	-$52.08M	-$40.97M	-$52.02M	-$47.67M	-$32.72M	-$6.701M	-$5.880M
YoY Change	-22.25%	29.55%	111.16%	26.0%	202.66%	-77.84%	27.12%	-21.25%	9.14%	45.69%	388.26%	13.96%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.11	-$3.78	-$3.93	-$2.81
Diluted Earnings Per Share	-$2.11	-$3.78	-$3.93	-$2.81	-$4.525M	-$39.13M	-$52.08M	-$52.53M	-$82.57M	-$119.2M	-$61.74M	-$12.64M	-$11.09M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$46.67M	$116.4M	$86.86M	$127.5M	$29.40M	$13.30M	$56.90M	$60.00M	$83.40M	$102.2M	$38.20M	$18.50M	$800.0K
YoY Change	-59.89%	33.97%	-31.87%	333.67%	121.05%	-76.63%	-5.17%	-28.06%	-18.4%	167.54%	106.49%	2212.5%
Cash & Equivalents	$46.67M	$106.7M	$86.86M	$127.5M	$29.40M	$13.30M	$56.90M	$60.00M	$83.40M	$102.2M	$38.20M	$4.500M	$800.0K
Short-Term Investments	$0.00	$9.629M										$14.00M	$0.00
Other Short-Term Assets	$5.157M	$9.194M	$17.85M	$6.000M	$2.900M	$900.0K	$1.200M	$1.500M	$1.600M	$2.600M	$5.700M	$700.0K	$100.0K
YoY Change	-43.91%	-48.48%	197.43%	106.9%	222.22%	-25.0%	-20.0%	-6.25%	-38.46%	-54.39%	714.29%	600.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$52.53M	$125.9M	$105.0M	$133.7M	$32.20M	$14.20M	$58.10M	$61.50M	$85.10M	$104.8M	$43.90M	$19.10M	$900.0K
YoY Change	-58.26%	19.88%	-21.47%	315.22%	126.76%	-75.56%	-5.53%	-27.73%	-18.8%	138.72%	129.84%	2022.22%
Property, Plant & Equipment	$1.765M	$1.846M	$1.100M	$1.100M	$700.0K	$700.0K	$2.200M	$2.500M	$3.800M	$3.100M	$2.500M	$1.200M	$1.100M
YoY Change	-4.39%	67.82%	0.0%	57.14%	0.0%	-68.18%	-12.0%	-34.21%	22.58%	24.0%	108.33%	9.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$43.00K	$42.00K	$0.00	$0.00	$0.00	$100.0K	$100.0K	$200.0K	$200.0K	$300.0K	$0.00	$0.00
YoY Change	-100.0%	2.38%				-100.0%	0.0%	-50.0%	0.0%	-33.33%
Total Long-Term Assets	$1.765M	$1.889M	$34.11M	$34.20M	$33.80M	$800.0K	$2.300M	$2.500M	$4.000M	$3.300M	$2.700M	$1.200M	$1.100M
YoY Change	-6.56%	-94.46%	-0.26%	1.18%	4125.0%	-65.22%	-8.0%	-37.5%	21.21%	22.22%	125.0%	9.09%
Total Assets	$54.30M	$127.8M	$139.1M	$167.9M	$66.00M	$15.00M	$60.40M	$64.00M	$89.10M	$108.1M	$46.60M	$20.30M	$2.000M
YoY Change
Accounts Payable	$5.099M	$4.281M	$3.745M	$3.700M	$2.400M	$300.0K	$1.000M	$800.0K	$1.200M	$1.200M	$1.200M	$1.100M	$900.0K
YoY Change	19.11%	14.31%	1.22%	54.17%	700.0%	-70.0%	25.0%	-33.33%	0.0%	0.0%	9.09%	22.22%
Accrued Expenses	$19.36M	$8.557M	$7.479M	$4.300M	$3.300M	$2.200M	$9.100M	$4.700M	$5.300M	$8.900M	$3.300M	$600.0K	$600.0K
YoY Change	126.24%	14.41%	73.93%	30.3%	50.0%	-75.82%	93.62%	-11.32%	-40.45%	169.7%	450.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due												$0.00	$500.0K
YoY Change												-100.0%
Total Short-Term Liabilities	$24.73M	$13.08M	$11.40M	$8.400M	$7.100M	$2.500M	$10.30M	$5.500M	$6.700M	$10.30M	$7.400M	$1.700M	$2.000M
YoY Change	89.1%	14.7%	35.73%	18.31%	184.0%	-75.73%	87.27%	-17.91%	-34.95%	39.19%	335.29%	-15.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$639.0K	$992.0K	$584.0K	$700.0K	$500.0K	$0.00	$100.0K	$100.0K	$100.0K	$200.0K	$300.0K	$0.00	$200.0K
YoY Change	-35.58%	69.86%	-16.57%	40.0%		-100.0%	0.0%	0.0%	-50.0%	-33.33%		-100.0%
Total Long-Term Liabilities	$639.0K	$992.0K	$584.0K	$700.0K	$500.0K	$0.00	$100.0K	$100.0K	$100.0K	$200.0K	$300.0K	$0.00	$200.0K
YoY Change	-35.58%	69.86%	-16.57%	40.0%		-100.0%	0.0%	0.0%	-50.0%	-33.33%		-100.0%
Total Liabilities	$25.37M	$14.07M	$11.99M	$9.100M	$7.600M	$2.600M	$10.30M	$5.600M	$6.800M	$10.50M	$7.800M	$1.800M	$2.200M
YoY Change	80.31%	17.39%	31.7%	19.74%	192.31%	-74.76%	83.93%	-17.65%	-35.24%	34.62%	333.33%	-18.18%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	44.32M shares	31.82M shares	23.65M shares	15.66M shares
Diluted Shares Outstanding	44.32M shares	31.82M shares	23.65M shares	15.66M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $161.24 Million

About Immunic Inc

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 77 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Industry: Pharmaceutical Preparations Peers: Adverum Biotechnologies Inc Bioxytran Inc Elutia Inc Checkpoint Therapeutics Inc CytomX Therapeutics Inc Galectin Therapeutics Inc OncoCyte Corp vTv Therapeutics Inc